Tianhong CNI BIOMEDICINE ETF(159859) Rises 3.06% Intraday,Earnings Season Boosts Sector Sentiment

NewTimeSpace News: As of 14:26 on March 27, 2026, the CSI Biomedical Index (399441) surged 3.52%. Among its constituent stocks, Bio-Thera Solutions rose 11.69%, Joinn Laboratories (China) Co., Ltd. jumped 10.00%, and Sino Biological Inc. climbed 8.93%. Dizhe Pharmaceutical Co., Ltd., Zhejiang WUHU Biotech Co., Ltd. and other stocks followed the upward trend. The Tianhong CNI BIOMEDICINE ETF(159859) rose 3.06% to a latest price of RMB 0.37. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, the Tianhong CNI BIOMEDICINE ETFrecorded an intraday turnover rate of 4.72% with a trading volume of RMB 187 million. Over a longer time frame, as of March 26, the ETF had an average daily trading volume of RMB 128 million in the past week, ranking first among comparable funds.

In terms of scale, the ETF's size has increased by RMB 12.3132 million in the past week, achieving a significant growth and ranking 1st among 3 comparable funds in terms of newly added scale. (Data source: Wind)

In terms of fund shares, the ETF's shares have increased by 218 million in the past week, with a remarkable growth and ranking 1st among 3 comparable funds in terms of newly added shares. (Data source: Wind)

In terms of capital flow, the ETF saw a latest net capital outflow of RMB 7.1793 million. Over a longer time frame, there were 3 days of net capital inflow in the past 5 trading days, with a total net inflow of RMB 93.975 million and an average daily net inflow of RMB 18.795 million. (Data source: Wind)

Data showed that leveraged funds have continued to build positions in the ETF. The cumulative margin net purchase volume of the Tianhong CNI BIOMEDICINE ETFhas reached RMB 2.0492 million since the start of the month, with the latest margin balance standing at RMB 209 million. (Data source: Wind)

In terms of earnings capacity, as of March 26, 2026, since its inception, the ETF has achieved a maximum monthly return of 27.87%, a longest consecutive monthly gain of 5 months with a cumulative increase of 31.58% during the period, and an average return of 5.50% in rising months. As of March 26, 2026, the ETF has an annualized excess return over the benchmark of 1.92% since its establishment.

In terms of drawdown, as of March 26, 2026, the Tianhong CNI BIOMEDICINE ETFhad a relative drawdown of 0.05% against the benchmark since the beginning of the year, recording the smallest drawdown among comparable funds.

In terms of fees, the Tianhong CNI BIOMEDICINE ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee level among comparable funds.

In terms of tracking accuracy, as of March 26, 2026, the ETF had a tracking error of 0.012% in the past three months, boasting the highest tracking accuracy among comparable funds.

From a valuation perspective, the latest Price-to-Earnings Ratio Trailing Twelve Months (PE-TTM) of the CSI Biomedical Index, which the Tianhong CNI BIOMEDICINE ETFtracks, is only 37.3 times, at the 17.65th percentile of the past year. That is, the valuation has been lower than the level seen in more than 82.35% of the time over the past year, standing at a historically low level.

The Tianhong CNI BIOMEDICINE ETFclosely tracks the CSI Biomedical Index. The index takes listed companies engaged in the biomedical industry on the Shanghai, Shenzhen and Beijing Stock Exchanges as its sample space, selects the top 30 securities as index constituent stocks based on a comprehensive ranking of market capitalization and liquidity, reflecting the overall operation of the biomedical industry and providing the market with an index investment target for the sub-sector.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Biomedical Index (399441) were WuXi AppTec Co., Ltd., Fosun Pharmaceutical (Group) Co., Ltd., Tigermed Consulting Co., Ltd., Shanghai RAAS Blood Products Co., Ltd., Changchun High-Tech Industrial (Group) Co., Ltd., Pharmaron Beijing Co., Ltd., Gan & Lee Pharmaceuticals Co., Ltd., Bio-Thera Solutions, Asymchem Laboratories (Tianjin) Co., Ltd. and Walvax Biotechnology Co., Ltd. in turn, accounting for a total of 55.33% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

Dongguan Securities stated that the market has now entered a period of intensive earnings disclosure, and the performance of some innovative pharmaceutical companies is expected to exceed expectations. With the continuous correction of the innovative pharmaceutical sector, the risk-reward ratio of investment in the sector has gradually improved.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.